NICE discount doesn't save Pixuvri from rejection; Antares nabs FDA nod for self-injected RA drug;

@FiercePharma: Biggest new news Monday: Irate Teva reps vow to strike against Israeli job cuts. Story | Follow @FiercePharma

@CarlyHFierce: Sanofi nabs OTC nod for Nasacort amid consumer healthcare push. ICYMI yesterday | Follow @CarlyHFierce

> The U.K.'s cost-effectiveness watchdog didn't budge on its rejection of Cell Therapeutics' ($CTIC) lymphoma drug Pixuvri, despite the company's offer of a discount. Report

> Antares Pharma won FDA approval for its drug Otrexup, a once-a-week, self-injected version of the standard oral treatment for rheumatoid arthritis and psoriasis, methotrexate. Report (sub. req.)

> The British pharma market is expected to hit $31.7 billion by 2010, GlobalData says, with good access to healthcare and a growing disease burden fueling growth. Report

> Cancer cases cost Europe €126 billion in 2009, including a €51 billion outlay on healthcare expenses; spending varied widely, from €16 per citizen in Bulgaria to €184 per capita in Luxembourg. Report

> A Madrid court yesterday heard Spain's first lawsuit against Germany's Grunenthal, which made the morning sickness drug thalidomide that caused birth defects in many babies. Report

> Of the 66 drugmakers that have received warning letters from the FDA since 2010, 12% were Indian companies, the Daily Mail found. Report

> Amid shortages of its usual execution drugs, Florida plans to execute a death-row inmate using the drug midazolam hydrochloride, despite worries that it may not work as promised. Report

Medical Device News

@FierceMedDev: Natera expands prenatal test amid global push. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Who are this year's FMD Fierce 15 winners? Find out here | Follow @MarkHFierce

@MichaelGFierce: Critical Diagnostics launches point-of-care cardiac disease test. Item | Follow @MichaelGFierce

> Covidien PAD treatments show promise in two trials. Article

> J&J's med tech biz falters amid weak sales, M&A rumors. Story

> Senate debt, government funding compromise avoids addressing device tax repeal. Report

Biotech News

@FierceBiotech: Analysts offer giddy forecasts for booming cancer immunotherapy pipeline. More | Follow @FierceBiotech

@JohnCFierce: PhIII blunders that have helped define companies, for better or worse. The top Phase III R&D setbacks of 2013 | Follow @JohnCFierce

@DamianFierce: If Myriad was a big dog in a small park in its fight with Ambry and Gene by Gene, Quest is a dog colossus. | Follow @DamianFierce

> Billionaire-backed immatics bags $46M to wrap cancer vaccine PhIII. Story

> JDRF, PureTech launch diabetes startup initiative. More

> AstraZeneca buys Spirogen in $440M deal, inks pact in armed antibody double-play. Story

> Aerie Pharma craves $84.5M in amped-up offering as IPOs pour in. More

> Sanofi plots more cuts at slow-footed French R&D shop. Article

Biotech Research News

@EmilyMFierce: Parkinson's may take two forms, one more toxic than the other. More | Follow @EmilyMFierce

> Vegetable-based compound protects against side effects of radiation therapy. Story

> Evotec gets $5.4M from Boehringer Ingelheim in cancer research pact. Report

> Compound halts neurodegeneration in mice. More

> Gene therapy plus stem cells quickens wound healing. Article

> Boston University, MRC Technology developing anti-inflammatory antibody. Item

Pharma Manufacturing News

@EricPFierce: MHRA says it also took action against Wockhardt contractor Nestor in U.K. as part of recent action. Article | Follow @EricPFierce

> U.S. awards special status to fired Novartis workers. Report

> Israeli unions threaten strikes over Teva job cuts. Item

> FDA closes out inspection on Ranbaxy New Jersey plant. More

> SAFC adds biologics capabilities at 2 plants. News

> Roche expanding biologics production in 3 countries. Story

And Finally... Can grandma's knees predict the weather? Scientists think they might. Report

Suggested Articles

Novartis is taking its MBC campaign to Instagram with a newly launched video series as part of the five-year “Make Your Dialogue Count” effort.

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more.